Global Non-Cancerous Blood Disease Market Report 2022: Growing Need for the Early Diagnosis of Different Types of Non-Cancerous Blood Diseases Driving Sector – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Non-Cancerous Blood Disease Market Analysis 2021-2031” report has been added to ResearchAndMarkets.com’s offering.

The global non-cancerous blood disease market is anticipated to grow with a CAGR of 6.40% over the forecast period, 2022 – 2031.

Factors such as the growing need for the early diagnosis of different types of non-cancerous blood diseases, followed by the surge in the burden for hemoglobinopathies across the globe, are anticipated to drive the growth of the market in the coming years.

Additionally, the increasing prevalence of non-cancerous blood disorders globally, along with the growing research and development in this field, followed by the surge in expenditure on R&D activities are also expected to boost the market growth in the coming years. The market is estimated to garner a revenue of near to USD 105970 Million by the end of 2031, up from a revenue of more than USD 57220 Million in the year 2021.

The global non-cancerous blood disease market is segmented into numerous segments, which include segmentation by disorder type, treatment type, gender, end-user, and by region.

By disorder type, the market is segmented into anemia, bleeding disorders, platelet disorders, white blood cell disorders, plasma cell disorders, rare hematological disorders, and spleen disorders.

By the end of 2031, the bleeding disorders segment is projected to display the largest revenue of close to USD 29950 Million, up from a revenue of about USD 16570 Million in the year 2021.

On the basis of regional analysis, the global non-cancerous blood disease market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in Europe region, out of the market in all the other regions, is anticipated to garner the largest revenue of over USD 39840 Million by the end of 2031. Additionally, in the year 2021, the market in the region generated a revenue of around USD 21340 Million.

Key Topics Covered:

1. Market Definition and Research Methodology

2. Executive Summary

3. Market Dynamics

4. Key Market Opportunities

5. Major Roadblocks for the Market Growth

6. Regulatory & Standards Landscape

7. Industry Risk Analysis

8. Analysis on Treatment Type

9. Epidemiology Analysis

10. R&D Pipeline Analysis

11. Proportion of Healthcare Expenditure (%) by Category and Blood Disorder Type, 2021

12. Analysis on the Existing Drug in the Market

13. Competitive Positioning

14. Competitive Structure

15. Global Non-Cancerous Blood Disease Market

16. North America Non-Cancerous Blood Disease Market

17. Europe Non-Cancerous Blood Disease Market

18. Asia Pacific Non-Cancerous Blood Disease Market

19. Latin America Non-Cancerous Blood Disease Market

20. Middle East & Africa Non-Cancerous Blood Disease Market

21. Primary Interview Analysis

22. Secondary Research Analysis

23. Methodology: Global Non-Cancerous Blood Disease Market

Companies Mentioned

• SANOFI
• Novo Nordisk A/S
• Novartis AG
• Pfizer Inc.
• Amgen Inc.
• Alexion Pharmaceuticals Inc.
• Bayer AG
• Bristol Myers Squibb Company
• F. Hoffmann-La Roche Ltd.
• Takeda Pharmaceutical Company Limited
• CSL Behring

For more information about this report visit https://www.researchandmarkets.com/r/jw6bkp

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900